FDA Flexible On Data Sources, Techniques For Pediatric Device Claims
This article was originally published in The Gray Sheet
Executive Summary
Computer modeling, Bayesian hierarchal modeling and use of off-label data sources are among novel methodologies that the device center may accept to demonstrate device effectiveness in kids, officials said Dec. 5.
You may also be interested in...
Adaptive Trials Guidance For Pediatric Drugs Will Draw On Device Advice
FDA’s centers may slingshot development work on how best to use control data.
Regulatory News In Brief
FDA misses some performance goals. Device center issues ombudsman’s report. DePuy stops selling custom devices. More regulatory briefs.
FDA Withdraws Pediatric Data-Submission Rule, But Aims To Regroup Shortly
FDA has 1withdrawn a new regulation that would have required companies to submit additional pediatric patient data as part of pre-market submissions beginning next month, but says it hopes to finalize a possibly revised version soon